107 related articles for article (PubMed ID: 23208613)
1. Engineering and refolding of a novel trimeric fusion protein TRAIL-collagen XVIII NC1.
Pan LQ; Xie ZM; Tang XJ; Wu M; Wang FR; Naranmandura H; Chen SQ
Appl Microbiol Biotechnol; 2013 Aug; 97(16):7253-64. PubMed ID: 23208613
[TBL] [Abstract][Full Text] [Related]
2. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Wang D; Shi L
Appl Biochem Biotechnol; 2009 Apr; 157(1):1-9. PubMed ID: 19306078
[TBL] [Abstract][Full Text] [Related]
3. Strategy for linker selection to enhance refolding and bioactivity of VAS-TRAIL fusion protein based on inclusion body conformation and activity.
Fan J; Huang L; Sun J; Qiu Y; Zhou J; Shen Y
J Biotechnol; 2015 Sep; 209():16-22. PubMed ID: 26072465
[TBL] [Abstract][Full Text] [Related]
4. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase.
Gasparian ME; Ostapchenko VG; Yagolovich AV; Tsygannik IN; Chernyak BV; Dolgikh DA; Kirpichnikov MP
Biotechnol Lett; 2007 Oct; 29(10):1567-73. PubMed ID: 17609857
[TBL] [Abstract][Full Text] [Related]
5. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
6. Efficient refolding of the bifunctional therapeutic fusion protein VAS-TRAIL by a triple agent solution.
Fan J; Wang Z; Huang L; Shen Y
Protein Expr Purif; 2016 Sep; 125():68-73. PubMed ID: 26358405
[TBL] [Abstract][Full Text] [Related]
7. TRAIL-CM4 fusion protein shows in vitro antibacterial activity and a stronger antitumor activity than solo TRAIL protein.
Sang M; Zhang J; Li B; Chen Y
Protein Expr Purif; 2016 Jun; 122():82-9. PubMed ID: 26926590
[TBL] [Abstract][Full Text] [Related]
8. Expression, purification and characterization of heterotrimeric forms of sTRAIL using a polycistronic expression vector.
Wang B; Wang Z; Yan J; Wang L; Wang Z; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
Protein Expr Purif; 2015 Nov; 115():118-24. PubMed ID: 26256060
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
10. A simplified method for the efficient purification and refolding of recombinant human TRAIL.
Zhang Z; Hahn SB; Cao TM; King MR
Biotechnol Prog; 2020 Sep; 36(5):e3007. PubMed ID: 32329219
[TBL] [Abstract][Full Text] [Related]
11. Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Lin Z; Lei H; Cao P
Protein Expr Purif; 2007 Feb; 51(2):276-82. PubMed ID: 17079165
[TBL] [Abstract][Full Text] [Related]
12. [Cloning, expression and purification of human TNF-related apoptosis-inducing ligand in Escherichia coli].
Yao GH; Luan JF; Ye D; Lei QH; Zhu PY; Jin J; Hou YY
Wei Sheng Yan Jiu; 2006 Nov; 35(6):697-700. PubMed ID: 17290744
[TBL] [Abstract][Full Text] [Related]
13. [Expression of a DNA fragment encoding the active domain of human TNF related apoptosis inducing ligand in pichia pastoris].
Xu H; Lai XT; Ye K; Ma HW; Hong K
Sheng Wu Gong Cheng Xue Bao; 2003 Mar; 19(2):163-7. PubMed ID: 15966315
[TBL] [Abstract][Full Text] [Related]
14. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
[TBL] [Abstract][Full Text] [Related]
15. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity.
Yan J; Wang L; Wang Z; Wang Z; Wang B; Zhu R; Bi J; Wu J; Zhang H; Wu H; Yu B; Kong W; Yu X
Cell Death Dis; 2016 Jun; 7(6):e2274. PubMed ID: 27336718
[TBL] [Abstract][Full Text] [Related]
16. Target cell-restricted apoptosis induction by 528scFv-TRAIL fusion protein specific for human EGFR and expressed in Escherichia coli.
Badran A; Asano R; Nakayama M; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kumagai I
Int J Oncol; 2010 May; 36(5):1229-34. PubMed ID: 20372797
[TBL] [Abstract][Full Text] [Related]
17. Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli.
Kang H; Sun AY; Shen YL; Wei DZ
Biotechnol Prog; 2007; 23(1):286-92. PubMed ID: 17269700
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events.
Sánchez-Arévalo Lobo VJ; Cuesta AM; Sanz L; Compte M; García P; Prieto J; Blanco FJ; Alvarez-Vallina L
Int J Cancer; 2006 Jul; 119(2):455-62. PubMed ID: 16477626
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor effect of combining interferon beta with TRAIL mediated by tumor-targeting adeno-associated virus vector on A549 lung cancer xenograft.
Wang Y; He L; He G; Kong Y; Liu X; Cai H; Liu X; Tan W
Sheng Wu Gong Cheng Xue Bao; 2010 Jun; 26(6):780-8. PubMed ID: 20815258
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
